<DOC>
	<DOCNO>NCT01527097</DOCNO>
	<brief_summary>Patients psoriasis seem increase risk develop atherosclerosis . This may due fact psoriasis atherosclerosis cause inflammation involvement cell immune system . Atherosclerosis frequently treat statin ( class cholesterol lower drug ) , low bad cholesterol level also reduce inflammation . Some new evidence also suggest therapy statin may improve psoriasis skin disease . The current study aim evaluate whether strong statin name Atorvastatin improve psoriatic skin disease function artery . The study also aim evaluate activity two disease related level common inflammatory biomarkers ( substance blood ) whether Atorvastatin change level .</brief_summary>
	<brief_title>Influence Atorvastatin Psoriasis Severity Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Patients older 20 year Patients psoriasis least 3years duration Current moderate severe psoriatic disease ( PASI ≥12 , IGA≥3 ) Statinnaïve patient No history cardiovascular disease ( ischemic heart disease , peripheral vascular disease cerebrovascular disease ) LDL level LDL level &gt; 70 mg % &lt; 160 mg % low risk patient ( define none single risk factor* ) LDL &gt; 70 mg % &lt; 130 mg % moderate risk patient ( define presence 2 risk factors* ) LDL &gt; 70 mg % &lt; 100 mg % patient type II diabetes hsCRP ≥ 1 mg/l * Risk factor : smoking , hypertension ( blood pressure &gt; 140/90 current treatment blood pressure lower agent , HDL &lt; 40 mg % , family history premature coronary artery disease first degree relative young 45 ( men ) 55 ( woman ) obesity ( BMI ≥ 30 ) . Current statin therapy Patents Atrial Fibrillation Elevated liver enzyme ( &gt; X3 ULN ) History statininduced liver enzyme elevation Elevated CPK level ( &gt; X3 ULN ) History myopathy include statininduced Severe chronic renal failure ( GFR &lt; 30 ml/min ) Pregnant breastfeed woman Individuals risk poor protocol , medication compliance Patients lifeexpectancy le 2 year Patients currently participate another clinical trial Other current active inflammatory and/or infectious condition Sensitivity atorvastatin ingredient Concomitant drug therapy , take regular basis , may interact Atorvastatin</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Inflammatory Disease</keyword>
	<keyword>Skin Disease</keyword>
</DOC>